These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 3053124)

  • 81. Present and future treatment of peptic ulcer and potential role of DE-NOL.
    Scand J Gastroenterol Suppl; 1982; 80():49-57. PubMed ID: 6761852
    [No Abstract]   [Full Text] [Related]  

  • 82. Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate.
    Elder JB
    Scand J Gastroenterol Suppl; 1986; 122():14-6. PubMed ID: 3535016
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Drugs for the prevention of peptic ulcer recurrence.
    Piper DW
    Drugs; 1983 Nov; 26(5):439-53. PubMed ID: 6315333
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists.
    Tytgat GN; Lamers CB; Hameeteman W; Jansen JM; Wilson JA
    Aliment Pharmacol Ther; 1987 Feb; 1(1):31-8. PubMed ID: 2908747
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Chemical structure of bismuth compounds determines their gastric ulcer healing efficacy and anti-Helicobacter pylori activity.
    Sandha GS; LeBlanc R; Van Zanten SJ; Sitland TD; Agocs L; Burford N; Best L; Mahoney D; Hoffman P; Leddin DJ
    Dig Dis Sci; 1998 Dec; 43(12):2727-32. PubMed ID: 9881506
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effect of bismuth subcitrate on amphibian gastroduodenal bicarbonate secretion.
    Shorrock CJ; Crampton JR; Gibbons LC; Rees WD
    Gut; 1989 Jul; 30(7):917-21. PubMed ID: 2788112
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Histological maturity of healed duodenal ulcers and ulcer recurrence after treatment with colloidal bismuth subcitrate or cimetidine.
    Pan SA; Liao CH; Lien GS; Chen SH
    Gastroenterology; 1991 Nov; 101(5):1187-91. PubMed ID: 1936788
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The potential impact of Campylobacter pylori on the treatment of duodenal ulcer disease.
    Miller JP; Faragher EB
    Scand J Gastroenterol Suppl; 1989; 160():39-45. PubMed ID: 2573145
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Bismuth therapy in gastrointestinal diseases.
    Gorbach SL
    Gastroenterology; 1990 Sep; 99(3):863-75. PubMed ID: 2199292
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pathogenesis and therapy of peptic ulcer disease.
    Peterson WL
    J Clin Gastroenterol; 1990; 12 Suppl 2():S1-6. PubMed ID: 1978840
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Implications of sucralfate-induced ulcer healing and relapse.
    Lam SK
    Am J Med; 1989 Jun; 86(6A):122-6. PubMed ID: 2660554
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Enhancement in gastric mucus gel qualities with colloidal bismuth subcitrate administration.
    Piotrowski J; Bilski J; Nishikawa H; Slomiany A; Slomiany BL
    Eur J Pharmacol; 1990 Aug; 184(1):55-63. PubMed ID: 2209715
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
    Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ
    Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate.
    Copeman M; Matuz J; Leonard AJ; Pearson JP; Dettmar PW; Allen A
    J Gastroenterol Hepatol; 1994; 9 Suppl 1():S55-9. PubMed ID: 7881020
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Effects of colloidal bismuth subcitrate and aluminum hydroxide on gastric and duodenal levels of prostaglandin E2].
    Estela R; Feller A; Backhouse C; Castro R; Ugarte G
    Rev Med Chil; 1984 Oct; 112(10):975-81. PubMed ID: 6399150
    [No Abstract]   [Full Text] [Related]  

  • 96. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate.
    Loffeld RJ; Potters HV; Stobberingh E; Flendrig JA; van Spreeuwel JP; Arends JW
    Gut; 1989 Sep; 30(9):1206-12. PubMed ID: 2680795
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Uncomplicated peptic ulcer disease. The therapeutic prospects and practice].
    Ubilluz Dhaga del Castillo R
    Rev Gastroenterol Peru; 1991; 11(1):40-8. PubMed ID: 1804328
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Some problems in modern anti-ulcer drug evaluation: a comparison of four gastric acid suppressors.
    Gibinski K
    Curr Med Res Opin; 1981; 7(8):516-9. PubMed ID: 6273068
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Campylobacter pylori: its link to gastritis and peptic ulcer disease.
    Marshall BJ
    Rev Infect Dis; 1990; 12 Suppl 1():S87-93. PubMed ID: 2406862
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine.
    Borkent MV; Beker JA
    Gut; 1988 Mar; 29(3):385-9. PubMed ID: 3281872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.